Terzuoli E, Donnini S, Giachetti A, Iiguez MA, Fresno M, Melillo G, Ziche M
June 20 Product: Sareptas Elevidys Indication: Duchenne muscular dystrophy Sarepta Therapeutics secured a much-anticipated expanded approval Thursday for Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD)
Given Ozempics role in blood sugar regulation, combining it with clarithromycin could potentially heighten this risk
Last week, meanwhile, Pfizer selected a once-daily formulation of its oral GLP-1 drug danuglipron as its preferred candidate for further development
Thus, its net effect is more about preservation rather than damage to hair pigment cells
Children generally require weight-adjusted regimens, often 100 mcg monthly after initial loading